Calculate your SIP ReturnsExplore

Stocks/Share Market - Angel One

These 3 Stocks from BSE 500 Jumped Over 5% Today; Do You Own Any?

These 3 Stocks from BSE 500 Jumped Over 5% Today; Do You Own Any?

23 July 2024

The benchmark index S&P BSE 500 opened today at 36,378.83 and made its day high at 36,386.09, and it is trading in red today, down by more than 0.10%. From the same space, these are the top 3 companies that outperformed the benchmark index and were up by more than 5% today. Easy Trip Planners …

Market Movers: Here Are Today’s High-Volume Buzzers!

Market Movers: Here Are Today’s High-Volume Buzzers!

23 July 2024

Benchmark indices started today’s trading session higher but quickly erased gains amidst uncertainties surrounding today’s Union Budget and the anticipated announcements that will shape market direction. Broader indices also struggled to gain momentum. Metals, oil and gas, energy, and financial services were among the top losers, while power, utilities, and capital goods sectors attempted to …

Upper Circuit Stocks Today – 23 July, 2024

Upper Circuit Stocks Today – 23 July, 2024

23 July 2024

On Tuesday, the benchmark indices were trading in the red with the Sensex down around 175 points or 0.21% at 80,350, while the Nifty-50 was down around 65 points or 0.26% at 24,444. About 1,506 shares have advanced; 1,958 declined and 175 are unchanged on the BSE. Top gainers and losers on the BSE Sensex …

Gland Pharma Receives Tentative USFDA Approval for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma Receives Tentative USFDA Approval for Latanoprostene Bunod Ophthalmic Solution

23 July 2024

On July 23, 2024, Gland Pharma Limited, a company specialising in generic injectable drugs, announced via a stock exchange filing that it has received tentative approval from the USFDA (US Food and Drug Administration ) for its Latanoprostene Bunod Ophthalmic Solution, 0.024%. This product is considered equivalent to Bausch & Lomb Inc.’s Vyzulta® Ophthalmic Solution, …

Mahindra Finance Q1FY25: Steady Growth, Strategic Expansion, and Digital Focus

Mahindra Finance Q1FY25: Steady Growth, Strategic Expansion, and Digital Focus

23 July 2024

Mahindra & Mahindra Financial Services Limited (Mahindra Finance), a leading NBFC in Emerging India, reported positive results for the quarter ended June 30, 2024 (Q1FY25). Here’s a breakdown of the key highlights: Financial Performance Business Assets: Grew 23% YoY to ₹1,06,339 crore, demonstrating a healthy loan portfolio. Disbursement: Maintained growth with ₹12,741 crore disbursed, reflecting …

L&T Technology Services and SymphonyAI Join Forces to Revolutionize Enterprise Operations with AI

L&T Technology Services and SymphonyAI Join Forces to Revolutionize Enterprise Operations with AI

23 July 2024

About Partnership L&T Technology Services (LTTS) and SymphonyAI have announced a strategic partnership to deliver cutting-edge AI-based solutions for enterprise operations. This collaboration leverages SymphonyAI’s Apex Enterprise Copilot, a powerful AI-driven platform, to transform IT service management (ITSM) and enhance overall business efficiency. The partnership aims to deliver transformative IT operations solutions to global customers …

Craftsman Automation Acquires INOS 24-004 GmbH

Craftsman Automation Acquires INOS 24-004 GmbH

23 July 2024

On July 23, 2024, Craftsman Automation Limited announced that it had acquired 100% of the equity shares of INOS 24-004 GmbH, a German company. This acquisition was carried out through a share sale and purchase agreement, making INOS 24-004 GmbH a wholly-owned subsidiary of Craftsman Automation. Additionally, INOS 24-004 GmbH owns INOS 24-003 GmbH, which …

Zydus Lifesciences Receives USFDA Approval for Valsartan Tablets

Zydus Lifesciences Receives USFDA Approval for Valsartan Tablets

23 July 2024

On July 23, 2024, Zydus Lifesciences Limited, along with its subsidiaries, announced that it had received final approval from the USFDA (United States Food and Drug Administration ) to market Valsartan Tablets USP in dosages of 40 mg, 80 mg, 160 mg, and 320 mg, which are equivalent to Diovan® tablets. Valsartan tablets treat high …

Coforge Delivers Strong Q1FY25 with Revenue Growth and Continued Momentum

Coforge Delivers Strong Q1FY25 with Revenue Growth and Continued Momentum

23 July 2024

Coforge Limited, a leading global IT solutions organisation, announced robust financial results for the quarter ended June 30, 2024 (Q1FY25), showcasing continued growth and industry recognition. Financial Highlights Paint a Positive Picture Revenue reached ₹24,008 crore (USD 291.4 million), reflecting a 1.6% increase quarter-on-quarter and a healthy 7.8% year-on-year growth on a constant currency basis. …

SRF Limited Q1FY25 Results: Mixed Performance with Packaging Films Buoyancy

SRF Limited Q1FY25 Results: Mixed Performance with Packaging Films Buoyancy

23 July 2024

SRF Limited, a diversified chemicals manufacturer, reported its consolidated financial results for the first quarter ended June 30, 2024 (Q1FY25). The results revealed a mixed performance with revenue growth but a decline in profitability. Revenue Up, Profitability Down Consolidated revenue increased marginally by 4% year-on-year (YoY) to ₹3,464 crore in Q1FY25. However, Earnings Before Interest …

Open Free Demat Account!
Enjoy Zero Brokerage on Stock Investments.